NFL and Novartis team up to address Prostate Cancer Myths and PSA testing at Super Bowl LX: "Relax, It's a Blood Test"
The National Football League and Novartis, a leading global innovative medicines company, launches a new awareness initiative timed to Super Bowl LX, starting the conversation to make critical health information clearer, accessible and relevant.
NFL Icons Coach Bruce Arians, Rob Gronkowski, George Kittle and more partner with Novartis to prioritize early prostate cancer detection. Novartis, a leading global innovative medicines company and the official pharmaceutical partner of the NFL, today announced the launch of "Relax, it's a blood test," a new national prostate cancer awareness initiative that kicks off with a commercial airing during Super Bowl LX on February 8, 2026.
The "Relax, it's a blood test" campaign cuts to the heart of the stigma and addresses the anxieties and misperceptions that can cause men to avoid prostate cancer screening. The initiative aims to normalize the process, empowering men to take control of their health with action. This ad highlights early detection, its accessibility, and lifesaving results.
The International Prostate Cancer Foundation recommends that PSA screening start for men between the ages of 30-45 years old. Talk with your physician for a screen timeline that is best for you.
The International Prostate Cancer Foundation believes that all men should have a chance to make informed decisions regarding their health. Routine screenings and checkups allow doctors to detect conditions and diseases in early stages. Remember that these tests aren't a substitute for regular medical care. Be sure to consult with your personal doctor on what testing plan is right for you. For the International Prostate Cancer Foundation’s recommendation on all Men’s health screenings view the infographic here.
Novartis is the official pharmaceutical partner of the NFL. Screening events with NFL teams, including onsite PSA testing, to support early detection and encourage proactive health decisions.